Molecular targeted therapy based on tyrosine kinase inhibitors (TKI), directed at epidermal growth factor receptor (EGFR) is one of the novel effective agents in management of advanced-stage of Non Small Cell Lung cancer (NSCLC). However several candidate predictors have been extensively studied, apart from activating EGFR gene mutations, no reliable biochemical or molecular predictors of response to erlotinib have been validated. The aim of our retrospective study was to evaluate the association of baseline serum albumin with outcomes in a large cohort of patients with advanced-stage NSCLC treated with erlotinib. Clinical data of 457 patients with locally-advanced (III B) or metastatic stage (IV) NSCLC treated with erlotinib were analysed. Serum samples were collected and the measurement was performed one day before the initiation of erlotinib treatment. Before the treatment initiation, low albumin was (<35 g/l) measured in 37 (8.1%) patients and normal albumin (≥ 35 g/l) was measured in 420 (91.9%). The median PFS and OS for patients with low serum albumin was 0.9 and 1.9 months compared to 1.9 and 11.4 months for patients with normal serum albumin (p=0.001 and p<0.001). The multivariate Cox proportional hazards model revealed that EGFR mutation status (HR=2.50; CI: 1.59-3.92; p<0.001) and pretreatment serum albumin (HR=1.73; CI: 1.21-2.47; p=0.003) were significant independent predictive factors for PFS, whereas EGFR mutation status (HR=3.14; CI: 1.70-5.81; p<0.001), stage (HR=1.48; CI: 1.09-2.02; p=0.013), ECOG PS (HR=1.77; CI: 1.37-2.29; p<0.001) and pretreatment serum albumin (HR=4.60; CI: 2.98-7.10; p<0.001) were significant independent predictive factors for OS. In conclusion, the results of present retrospective study indicate that pretreatment hypoalbuminemia is associated with poor outcome of NSCLC patients treated with erlotinib. Based on these results, measuement of serum albumin is an objective laboratory method feasible for estimation of prognosis of patients with advanced-stage NSCLC.
Lung cancer is the principal cause of cancer-related mortality in developed countries [1, 2] . Non-small cell lung cancer (NSCLC) is the most common histological type constituting more than 80% of all lung carcinomas [3] . Molecular targeted therapy based on tyrosine kinase inhibitors (TKI), directed at epidermal growth factor receptor (EGFR) is one of the novel effective agents in management of advanced-stage NSCLC. Erlotinib is a reversible EGFR-TKI that inhibits the EGFR tyrosine kinase by competing with adenosine triphosphate (ATP) at the ATP-binding site and prevents its phosphorylation and downstream signaling. However several candidate predictors have been extensively studied, apart from activating EGFR gene mutations, no reliable biochemical or molecular predictors of response to erlotinib have been validated. Patients with advanced NSCLC frequently present with malnutrition and subsequently, with hypoalbuminemia [4, 5] . Accumulating data has highlighted a correlation between hypoalbuminemia and survival in cancer patients. Hypoalbuminemia has been reported as a negative prognostic factor for survival in patients with colorectal carcinoma [6, 7] , gastric carcinoma [8] , breast cancer [9] and NSCLC [10] . The aim of our retrospective study was to evaluate the association of baseline serum albumin with outcomes in a large cohort of patients with advanced-stage NSCLC treated with erlotinib.
Patients and methods
Patients and treatment. We retrospectively analysed clinical data of 457 patients with cytologically or histologically confirmed locally-advanced (IIIB) or metastatic stage (IV) NSCLC treated with erlotinib. Patients were treated between years 2005 and 2014. Erlotinib was administered orally at the standard approved dose of 150 mg daily. The treatment was continued until disease progression or development of intolerable toxic effects. Dose interruption or reduction was permitted in the event of treatment-related toxicity.
Data source. The clinical registry TULUNG (http://tulung. registry.cz/), in which Faculty Hospital Pilsen is participating since its creation, is a non-interventional post-registration database of epidemiological and clinical data of patients with advanced-stage NSCLC treated with targeted therapies in the Czech Republic. The registry contains anonymised individual patient data including demographic parameters, initial staging and disease characteristics, baseline patient information at the start of targeted therapy, as well as data on survival and adverse events which is updated at least twice a year. Data on pretreatment serum levels of albumin were extracted from the hospital information system and merged to the registry data. The protocol was approved by the independent ethics committee of the University Hospital Pilsen and complied with the International Ethical Guidelines for Biomedical Research Involving Human Subjects, Good Clinical Practice guidelines, the Declaration of Helsinki, and local laws.
Clinical monitoring. The treatment was prospectively monitored and the clinical course of patients was continuously assessed at specific time points. Clinical follow-up controls including physical examination, plain chest X-ray and routine laboratory tests was performed every 3-4 weeks; computed tomography (CT) or positron emission tomography -(PET)-CT was performed after two or three months of the treatment. The objective tumor response was assessed by investigators using Response Evaluation Criteria in Solid Tumors (RECIST) [11] .
Albumin measurement. Serum samples were collected and the measurement was performed one day before the initiation of erlotinib treatment. Serum albumin was measured with bromcresol green, supplied by Beckman Coulter (Brea, CA, USA) on an AU 2700 or AU 5800 (since 2014) analyzers from Beckman Coulter. The measurement was performed in the central biochemical laboratory at the Department of Clinical Biochemistry and Hematology, Medical School and Teaching Hospital in Pilsen, using the cut-off value of 35 g/l, which is the normal value measured by the used test.
EGFR mutation analysis. The tumor specimens acquired during initial bronschoscopy examination were evaluated by a senior cytologist using standard giemsa staining. In a few cases, a tumor biopsy was processed into formalin-fixed paraffin embedded (FFPE) histological sections. The cytology slides or, eventually, the FFPE sections, were submitted for molecular genetic testing, which included detection of somatic mutations in exon 19 (deletion) and 21 (L858R) of EGFR gene. If necessary, tumor cells were carefully selected and removed from the samples by laser microdissection using a P.A.L.M. microlaser instrument (Carl Zeiss MicroImaging GmbH, Jena, Germany). The microdissected cells were collected directly into the polymerase chain reaction (PCR) buffer and processed without a special DNA extraction step. In all other cases, the DNA was extracted from tissue cells by a standard spin column procedure using JetQuick Tissue DNA Issolation Kit (Genomed GmbH, Loehne, Germany). Mutations were tested by Genoscan mutation detection kits (Genomac International, Prague, Czech Republic) utilizing a denaturing capillary electrophoresis (DCE) technique on an ABI PRISM 3100 16-capillary genetic analyzer (Applied Biosystems, Foster City, CA, USA). Detected mutations were confirmed by Sanger DNA sequencing using a BigDye v 3.0 chemistry (Applied Biosystems, Foster City, CA, USA). In rare cases, where the overall fraction of mutated DNA was below the 20% threshold for DNA sequencing, mutation was identified indirectly after forming only a homoduplex fragment with a given known mutation reference standard.
Statistics. Standard frequency tables and descriptive statistics were used to characterize sample data set. MannWhitney test was used for comparison of albumin between different subgroups of patients. . PFS and OS were estimated using Kaplan Meier method and all point estimates were accompanied by 95% confidence intervals. Progression-free survival (PFS) was defined from the date of erlotinib initiation until the date of first documented progression or death. Overall survival (OS) was defined from the date of erlotinib initiation until the date of death due to any cause. Patients who had not progressed or died were censored at the date of last follow-up. Statistical significance of the differences in Kaplan-Meier estimates was assessed using the log-rank test. Multivariable Cox proportional hazards model was used to evaluate the effect of all potential prognostic factors on the survival measures. Statistical significance of hazard ratios were assessed by means of Wald test. As a level of statistical significance α=0.05 was used. Table 1 . The median follow-up of the cohort was 6.5 months, the median OS was 10.4 months (95% CI: 8.3-12.5), and the median PFS was 1.9 months (95% CI: 1.8-2.1).
Results

Patient
Baseline serum albumin levels. Before the treatment initiation, low albumin was (<35 g/l) measured in 37 (8.1%) patients and normal albumin (≥ 35 g/l) was measured in 420 (91.9%). Low baseline albumin levels were significantly associated with worse ECOG PS (p<0.001) and treatment in higher line (p=0.001).
Relation between baseline serum albumin and survival. The median PFS and OS for patients with low serum albumin was 0.9 and 1.9 months compared to 1.9 and 11.4 months for patients with normal serum albumin (p=0.001 and p<0.001). The PFS and OS data are summarized in Table 2 and survival curves are shown in Figure 1 . Baseline clinical parameters were assessed together with serum albumin levels multivariate model. 
Discussion
Albumin is the most abundant protein in human blood plasma and constitutes approximately half of the blood serum protein. It is produced by the liver cells and maintains intravascular oncotic pressure, transports hormones, fatty acids and other compounds and buffers blood pH among other functions. Malnutrition and systemic inflamatory response (SIR) suppress albumin synthesis [12] . The normal serum albumin level in adults ranges between 35 and 50 g/l. Serum albumin concentration has been regularly used as a biochemical marker of long-term nutritional status; it is one of the easiest parameters to measure and that which best reflects the state of visceral protein [13] . Decrease of albumin serum levels reflects both the loss of the amount of lean tissue and SIR [14] [15] [16] [17] . Malnutrition commonly occurs in cancer patients. Patients with advanced NSCLC have an important energy expenditure caused by increased tumor metabolism [18] . Those patients frequently present with malnourishment and subsequently, with hypoalbuminemia [4, 5, 19, 20] caused by tumor activity via increased fractional catabolic rate (FCR) and also by decreased albumin synthesis. Notably, the majority of patients suffer from loss of appetite [21] resulting in diminished food intake [22] .
Randomised phase III clinical trials demonstrated efficacy and safety of erlotinib in the treatment of patients with advanced-stage NSCLC [23] [24] [25] [26] . Increasing evidence suggests that proper patient selection through the identification and use of predictive biomarkers may maximize the efficacy of targeted anticancer therapies. It has been well-established that activating EGFR gene mutations encoding the tyrosine kinase domain (predominantly the exon 19 deletions or the point mutations in exon 21 termed L858R) predict favourable response to the treatment with EGFR-TKIs in patients with advanced-stage NSCLC [27] [28] [29] [30] . On the other hand, the efficacy of EGFR-TKIs in the predominant group of NSCLC patients harbouring wild-type EGFR gene, is low and there is no available predictive biomarker. Several studies have shown that malnutrition has been associated with worse performance status, reduced quality of life (QoL), increased hospitaliza- [35] . Notably, the multivariate Cox proportional hazards model showed that hypoalbuminemia was the strongest factor predicting OS, even stronger than EGFR mutation, stage or ECOG PS. Moreover, basic nutritional screening using serum albumin measurement might allow identification of high-risk patients and the implementation of an intensive nutritional support might be beneficial. The principal limitations of the present study are the retrospective nature and relatively limited number of patients with hypoalbuminemia.
In conclusion, the results of the present retrospective study indicate that pretreatment hypoalbuminemia is associated with poor outcome of NSCLC patients treated with erlotinib. Based on the present study results, measuement of serum albumin is an objective laboratory method feasible for estimation of prognosis of patients with advanced-stage NSCLC.
